COMPARATIVE TRIAL OF ANTIANGINAL DRUGS IN STABLE CORONARY HEART DISEASE
- Authors: Bulakhova E.1,2, Korennova O.1, Kondrasheva M.2, Kamlonko O.2, Pasechnaya N.2
-
Affiliations:
- Omsk State Medical Academy
- City Clinical Hospital Four, Omsk
- Issue: Vol 24, No 9 (2013)
- Pages: 50-54
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115804
- ID: 115804
Cite item
Open Access
Access granted
Abstract
Nicorandil has a number of advantages over nitrates in treating stable angina pectoris. Thus, enhanced exercise tolerance is accompanied by a significant improvement in the indicators of brain blood supply, better erectile function and quality of life, lower admission rates, and better tolerance. The findings are important in choosing drug therapy policy in this category of patients.
Full Text
About the authors
E. Bulakhova
Omsk State Medical Academy; City Clinical Hospital Four, Omsk
Email: sab.pro@mail.ru
O. Korennova
Omsk State Medical Academy
M. Kondrasheva
City Clinical Hospital Four, Omsk
O. Kamlonko
City Clinical Hospital Four, Omsk
N. Pasechnaya
City Clinical Hospital Four, Omsk
References
- Национальные клинические рекомендации ВНОК, 2010; 369 с.
- Ольбинская Л., Морозова Т., Сизова Ж. и др. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей / М.: Медицина, 2006; 386 с.
- Horinaka S. Use of nicorandil in cardiovascular disease and its optimization // Drugs. - 2011; 71 (9): 1105-19.
- Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. - 2011; 214 (2): 415-21.
- Kinoshita M., Sakai K. Pharmacology and Therapeutic Effects of Nicorandil. Cardiovacs // Drugs and Therapy. - 1990; 4: 1075-88.
- Meany T., Richardson P., Camm A. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris // Am. J. Cardiol. -1989; 63: 66-70.
- Okura T., Higaki J., Kurata M. et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study // Circ. J. - 2009; 73: 885-91.
- Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. - 2004; 68: 232-56.
- Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. - 2012; 59 (1): 14-21.
- Sekiya M., Sato M., Funada J., Ohtani T. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. - 2005; 46 (1): 63-7.
Supplementary files
